Literature DB >> 11008097

Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions.

.   

Abstract

Purpose: Yttrium-86 has been proposed for use as a quantitative positron emission tomography imaging agent to determine the in vivo distribution of therapeutic pharmaceuticals labeled with yttrium-90, a pure beta minus emitter. This study identifies, and proposes a solution for, an artifact, which interferes with quantitation.Procedures: Yttrium-86 is a 14.7-hour halflife positron emitter (33% abundance) with multiple high energy gamma rays in cascade. Phantom measurements with a GE Advance PET scanner using standard attenuation and scatter corrections, demonstrated anomalous apparent activity in inactive higher density regions.
Results: Apparent activity up to 30% of the surrounding true activity was observed in a bone equivalent material. Even higher activities were observed if the scatter correction was omitted. This phenomenon was determined to result from the effect of attenuation correction on true coincidences between one gamma ray and a second gamma ray or annihilation photon.
Conclusion: A simple additional correction based on sinogram tail subtraction improves accuracy significantly.

Entities:  

Year:  2000        PMID: 11008097     DOI: 10.1016/s1095-0397(00)00046-7

Source DB:  PubMed          Journal:  Clin Positron Imaging        ISSN: 1095-0397


  18 in total

1.  PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction.

Authors:  H G Buchholz; H Herzog; G J Förster; H Reber; O Nickel; F Rösch; P Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-26       Impact factor: 9.236

2.  Is PET always an advantage versus planar and SPECT imaging?

Authors:  Giuliano Mariani; Laura Bruselli; Adriano Duatti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 3.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

4.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

Review 5.  Accuracy and precision of radioactivity quantification in nuclear medicine images.

Authors:  Eric C Frey; John L Humm; Michael Ljungberg
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

Review 6.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 7.  Quantitative imaging of 124I and 86Y with PET.

Authors:  Mark Lubberink; Hans Herzog
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 8.  Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.

Authors:  Sabrina Rossi; Luca Toschi; Angelo Castello; Fabio Grizzi; Luigi Mansi; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-16       Impact factor: 9.236

9.  Correction technique for cascade gammas in I-124 imaging on a fully-3D, Time-of-Flight PET Scanner.

Authors:  Suleman Surti; Ryan Scheuermann; Joel S Karp
Journal:  IEEE Trans Nucl Sci       Date:  2009-06       Impact factor: 1.679

10.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Authors:  Sarah M Cheal; Hong Xu; Hong-Fen Guo; Sang-Gyu Lee; Blesida Punzalan; Sandhya Chalasani; Edward K Fung; Achim Jungbluth; Pat B Zanzonico; Jorge A Carrasquillo; Joseph O'Donoghue; Peter M Smith-Jones; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.